Bullfrog AI Holdings, Inc. Common Stock

Bullfrog AI Holdings, Inc. Common Stock

BFRG
Bullfrog AI Holdings, Inc. Common StockUS flagNASDAQ Capital Market
0.77
USD
+0.07
- -
8.17MMarket Cap
Bullfrog AI Holdings, Inc. Common Stock
BFRG
(NASDAQ Capital Market)

Recent

price

0.77

P/E

ratio

- -

div

yld

- -

ROIC.AI

2020
2021
2022
2023
2024
2025
TTM
FRC
- -
- -
- -
0.01
- -
- -
0.01
Revenue per Share
-0.06
-0.1
-0.49
-0.89
-0.85
- -
-0.55
Basic EPS, GAAP
-0.04
-0.07
-0.16
-0.99
-0.68
- -
-0.49
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-0.18
-0.28
-0.78
-1.61
-2.04
- -
-2.26
Book Value per Share
-0.1
-0.18
-0.54
0.43
0.6
- -
0.44
Tangible Book Value per Share
6
6
6
6
8
- -
11
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
-24,558.01
-8,257.73
- -
-5,652.38
-5,273.54
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
-1
-3
-5
-7
-6
-6
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
-28,024.87
-8,239.8
- -
-5,569.61
-5,205.86
Profit Margin (%)
-1
-1
-3
3
5
2
5
Working Capital
- -
- -
- -
- -
- -
- -
- -
LT Debt
-1
-1
-3
3
5
2
5
Total Equity
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
10
11
18
Market Capitalization
14
9
18

Working Capital

FRC

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
3
3
5
Cash, Cash Equivalents & STI
2
2
5
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
1
1
1
Payables & Accruals
1
1
1
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
27.88%
-56.96%
Free Cash Flow
- -
153.12%
-1.57%
Net Income, GAAP
- -
112.88%
-7.09%
Sales/Revenue/Turnover
- -
- -
79.49%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.26
-0.2
-0.22
- -
-0.85
2025
-0.21
-0.15
-0.15
- -
- -
2026
-0.12
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
BullFrog AI Holdings, Inc. is a technology-enabled digital biopharmaceutical company specializing in the use of advanced artificial intelligence and machine learning (AI/ML) to improve drug development and clinical trials. Founded in 2017 and headquartered in Gaithersburg, Maryland, BullFrog AI develops and markets its proprietary analytical AI/ML platform, bfLEAP™, which provides complex data analysis for preclinical and clinical datasets to identify high-value data niches and patient subgroups. The company's core products include the bfLEAP™ platform for drug discovery, clinical trial optimization, drug repurposing, and biomarker identification, along with the BullFrog Data Networks™ Solutions Library and the newly launched bfPREP™ module for automated data cleansing and standardization. BullFrog AI primarily serves biotechnology and pharmaceutical companies in the United States, leveraging AI to accelerate and de-risk drug discovery and development, particularly targeting diseases such as CNS disorders, hepatocellular carcinoma, obesity, and non-alcoholic fatty liver disease. Recent strategic developments include a major collaboration agreement with Sygnature Discovery to expand BullFrog AI's presence in international biopharma R&D markets, focusing on early-stage target discovery and precision medicine. In 2025, BullFrog AI has also launched the bfPREP™ module to enhance data processing capabilities and completed a registered direct offering raising approximately $3.13 million to fund ongoing platform development and operational expansion. The company has recognized initial commercial revenue in 2025 and continues to pursue partnerships and internal initiatives aimed at broadening the applications of its AI-driven technology in drug development. BullFrog AI's business model emphasizes AI-driven efficiency for biopharma R&D, targeting improved clinical outcomes, reduced costs, and precise patient stratification to transform drug discovery and clinical trial processes.

Company News

APIChat
  • BullFrog AI Announces New Commercial Leadership Team to Execute Growth Strategy for its Integrated Pharma AI Platform

  • BullFrog AI Regains Compliance with Nasdaq Shareholders' Equity Requirement

  • BullFrog AI Announces Participation at AACR Annual Meeting

  • BullFrog AI Provides Business Update: Strengthened Balance Sheet Supports Continued Execution as Company Aims to Ramp Commercial Activity with Global Pharmaceutical and Biotechnology Partners

  • Bullfrog AI Holdings Inc. (NASDAQ:BFRG) Short Interest Down 15.0% in March

  • BullFrog AI Shares Surge On Deal With Top Pharma Company For MDD Drug Targets

  • Bullfrog AI stock offers a rare opportunity for investors to take profit

  • Dow Gains 200 Points; Bullfrog AI Shares Jump

  • BullFrog AI Announces Commercial Agreement with Top 5 Global Pharmaceutical Company to Identify and Prioritize Therapeutic Target in Major Depressive Disorder

  • BullFrog AI Unveils bfARENAS™ Scenario-based Decision Engine

  • BullFrog to Host Webinar on New Precision AI Capability

  • Head to Head Review: Talkspace (NASDAQ:TALK) vs. Bullfrog AI (NASDAQ:BFRG)

  • Bullfrog AI (NASDAQ:BFRG) Stock Price Down 16.5% – Here’s What Happened

  • BullFrog AI to Unveil New Precision AI Capability

  • Financial Comparison: Hinge Health (NYSE:HNGE) versus Bullfrog AI (NASDAQ:BFRG)

  • BullFrog AI-Driven Precision Oncology Analytics Identifies 3x Increase in Overall Survivability in Patient Subgroups through Key Biomarkers in Pancreatic Cancer

  • Contrasting Bullfrog AI (NASDAQ:BFRG) & Fulgent Genetics (NASDAQ:FLGT)

  • Careview Communications (OTCMKTS:CRVW) versus Bullfrog AI (NASDAQ:BFRG) Critical Review

  • Bullfrog AI (NASDAQ:BFRG) Trading Down 5.7% – Time to Sell?

  • Critical Analysis: Bullfrog AI (NASDAQ:BFRG) versus Patient Portal Technologies (OTCMKTS:PPRG)